Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 2,084 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: Glendale, Arizona • Phoenix, Arizona • Upland, California + 7 more

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Aptensio XR; Drug
Lead sponsor: Rhodes Pharmaceuticals, L.P.; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Las Vegas, Nevada • Durham, North Carolina

Conditions: Healthy
Interventions: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Psoriasis, Plaque Psoriasis
Interventions: Certolizumab Pegol, Placebo; Biological · Other
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 14
States / cities: Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more

Conditions: Attention Deficit Hyperactivity Disorder, ADHD
Interventions: Methylphenidate Hydrochloride Extended Release Capsules, Placebo; Drug
Lead sponsor: Rhodes Pharmaceuticals, L.P.; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 16
States / cities: Little Rock, Arkansas • Irvine, California • National City, California + 13 more

Conditions: Hyperphagia, Prader-Willi Syndrome, Hyperphagia in Prader-Willi Syndrome
Interventions: ARD-101; Drug
Lead sponsor: Aardvark Therapeutics, Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 16
States / cities: Birmingham, Alabama • Orange, California • Palo Alto, California + 13 more

Conditions: Overactive Bladder
Interventions: Oxybutynin topical gel, Placebo topical gel; Drug · Other
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 789 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 63
States / cities: Birmingham, Alabama • Homewood, Alabama • Mobile, Alabama + 60 more

Conditions: Eosinophilic Gastritis, Eosinophilic Duodenitis
Interventions: lirentelimab; Drug
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 38
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 30 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Edasalonexent; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 4 Years to 12 Years · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 15
States / cities: Sacramento, California • Atlanta, Georgia • Iowa City, Iowa + 11 more

Conditions: Low Back Pain, Osteoarthritis, Neuropathic Pain
Interventions: EN3409; Drug
Lead sponsor: BioDelivery Sciences International; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 57
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 52 more

Conditions: Schizophrenia
Interventions: Pimavanserin; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 995 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more

Conditions: Huntington Disease
Interventions: RO7234292 (RG6042); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 25 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 14
States / cities: Birmingham, Alabama • La Jolla, California • Palo Alto, California + 11 more

Conditions: Canavan Disease
Interventions: rAAV-Olig001-ASPA, Levetiracetam, Prednisone; Drug
Lead sponsor: Myrtelle Inc.; Industry
Eligibility: 3 Months to 60 Months
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Spinal Cord Injury, Bone Loss, Osteoporosis
Interventions: Alendronate, Calcium, Vitamin D; Drug · Dietary Supplement
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pulmonary Hypertension Associated With HFpEF
Interventions: Oral treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 82
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 56
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more

Conditions: Acute Gout
Interventions: Canakinumab 150 mg, Triamcinolone acetonide 40 mg, Placebo to canakinumab, Placebo to triamcinolone acetonide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 96
States / cities: Anniston, Alabama • Birmingham, Alabama • Foley, Alabama + 81 more

Conditions: Attention Deficit/Hyperactivity Disorder, ADHD
Interventions: Modafinil; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 6 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 57
States / cities: Birmingham, Alabama • Mesa, Arizona • Fort Smith, Arkansas + 53 more

Conditions: Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation
Interventions: BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2, BAY2927088_formulation B_3; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 11
States / cities: Gilbert, Arizona • Duarte, California • Atlanta, Georgia + 7 more

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Dinesh Khanna, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 23
States / cities: Los Angeles, California • Redwood City, California • Washington D.C., District of Columbia + 17 more

Conditions: Thalassemia
Interventions: AG-348; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 2
States / cities: Oakland, California • Boston, Massachusetts

Conditions: Sjögren's Syndrome
Interventions: Dazodalibep; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 844 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 31
States / cities: Avondale, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 27 more

Conditions: CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
Interventions: Fenfluramine, Placebo; Drug
Lead sponsor: Zogenix, Inc.; Industry
Eligibility: 1 Year to 35 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more

Conditions: Hair Thinning
Interventions: Active Comparator- Xtressé™ Supplement and Serum, Placebo Comparator- Placebo Supplement and Serum; Dietary Supplement
Lead sponsor: The Center for Clinical and Cosmetic Research; Other
Eligibility: 28 Years to 65 Years · Female only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Birmingham, Alabama • Aventura, Florida

Search by objective public record fields.

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD

The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

Long-term Open-Label Safety Study to Evaluate EN3409

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies

rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease

Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.

Evaluate the Safety and Efficacy of Modafinil in Children and Adolescents With ADHD

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis

A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair